SCHEMBL5570907

SCHEMBL5570907

CN1CCC(N)(CN)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14413873 0.86 ROCK2 (0.33)
SCHEMBL3506624 0.85 NCF1 (0.37)
SCHEMBL21958687 0.81
SCHEMBL14311987 0.79
Hydrochloric Acid SCHEMBL14311821 0.77 DRD4 (0.34)
SCHEMBL22996642 0.76 SLC6A2 (0.36)
SCHEMBL89531 0.76 DRD4 (0.33)
SCHEMBL22996645 0.76 SLC6A2 (0.36)
SCHEMBL22996646 0.74 DRD4 (0.32)
SCHEMBL25583812 0.74 DRD4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
US-7202246-B2 Spiro-rifamycin derivatives targeting RNA polymerase CUMBRE PHARMACEUTICALS INC. (US) 2007-04-10 US disclosed
US-20050277633-A1 E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria CUMBRE INC. (US) 2005-12-15 US disclosed